CEO to review dronabinol, a Phase 3-ready medicine for the treatment of obstructive sleep apnea, and provide pipeline update
GLEN ROCK, NJ — (Marketwired) — 12/23/16 — RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) ("RespireRx" or the "Company"), is pleased to announce positive results of the PACE (Pharmacotherapy of Apnea by Cannabimimetic Enhancement) trial conducted by Dr. David Carley and colleagues at the University of Illinois at Chicago and Northwestern University. The PACE trial, a Phase 2B study of dronabinol for the treatment of obstructive sleep apnea ("OSA"), clearly demonst
© 2020 88Finance. All Rights Reserved. Log in - Copyright by LayerMedia
